Issues
-
Cover Image
Cover Image
Malignant mesothelioma cells secrete the damage-associated molecular pattern protein HMGB1 that promotes tumor progression and sustains the malignant phenotype. HMGB1-secreting mesothelioma cells are addicted to HMGB1, and their anchorage independent growth is impaired by the antagonist BoxA or by a HMGB1 specific monoclonal antibody (mAb), or by a mAb against HMGB1 receptor RAGE, as indicated by the reduced number and size of colonies, compared to controls. For details, see article by Jube et al. on page 3290 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Perspective
Priority Report
Integrated Systems and Technologies
Microenvironment and Immunology
Breast Cancer Cell Uptake of the Inflammatory Mediator Neutrophil Elastase Triggers an Anticancer Adaptive Immune Response
Molecular and Cellular Pathobiology
Histone Lysine Methyltransferase SETD8 Promotes Carcinogenesis by Deregulating PCNA Expression
Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression
Prevention and Epidemiology
Therapeutics, Targets, and Chemical Biology
Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth
Tumor and Stem Cell Biology
Definition of Genetic Events Directing the Development of Distinct Types of Brain Tumors from Postnatal Neural Stem/Progenitor Cells
PTEN and NF1 Inactivation in Schwann Cells Produces a Severe Phenotype in the Peripheral Nervous System That Promotes the Development and Malignant Progression of Peripheral Nerve Sheath Tumors
CD44s Regulates the TGF-β–Mediated Mesenchymal Phenotype and Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.